24. van GE, Weimar W, Gaston R, Brennan D, Mendez R, et al. (2008) Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics. Am J Transplant 8: 1711–1718. 25. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, et al. (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363: 1117–1127. 26. Luo C, Laaja P (2004) Inhibitors of JAKs/STATs and the kinases: a possible new cluster of drugs. Drug Discov Today 9: 268–275. 27. Kirken RA, Erwin RA, Taub D, Murphy WJ, Behbod F, et al. (1999) Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells. J Leukoc Biol 65: 891–899. 28. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, et al. (1996) Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379: 645–648. 29. O’Shea JJ (1997) Jaks, STATs, cytokine signal transduction, and immunoreg- ulation: are we there yet? Immunity 7: 1–11. 30. O’Shea JJ, Pesu M, Borie DC, Changelian PS (2004) A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat Rev Drug Discov 3: 555–564. 31. Wang LH, Kirken RA, Erwin RA, Yu CR, Farrar WL (1999) JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response. J Immunol 162: 3897–3904. 32. Bright JJ, Du C, Sriram S (1999) Tyrphostin B42 inhibits IL-12-induced tyrosine phosphorylation and activation of Janus kinase-2 and prevents experimental allergic encephalomyelitis. J Immunol 162: 6255–6262. 33. Constantin G, Brocke S, Izikson A, Laudanna C, Butcher EC (1998) Tyrphostin AG490, a tyrosine kinase inhibitor, blocks actively induced experimental autoimmune encephalomyelitis. Eur J Immunol 28: 3523–3529. 34. Constantin G, Laudanna C, Brocke S, Butcher EC (1999) Inhibition of experimental autoimmune encephalomyelitis by a tyrosine kinase inhibitor. J Immunol 162: 1144–1149. 35. Behbod F, Erwin-Cohen RA, Wang ME, Trawick BW, Qu X, et al. (2001) Concomitant inhibition of Janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts. J Immunol 166: 3724–3732. 36. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, et al. (2003) Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302: 875–878. 37. Davoodi-Semiromi A, Laloraya M, Kumar GP, Purohit S, Jha RK, et al. (2004) A mutant Stat5b with weaker DNA binding affinity defines a key defective pathway in nonobese diabetic mice. J Biol Chem 279: 11553–11561. 38. Davoodi-Semiromi A, McDuffie M, Litherland S, Clare-Salzler M (2007) Truncated pStat5B is associated with the Idd4 locus in NOD mice. Biochem Biophys Res Commun. 39. Davoodi-Semiromi A, Cheikhi A, Xia C, Litherland S, Clare-Salzler M (2007) Modulation of CD4+Foxp32 T-cells with a JAK-STAT5 kinase inhibitor. J Immunol 178: S237–S23c. 40. Gilmour KC, Pine R, Reich NC (1995) Interleukin 2 activates STAT5 transcription factor (mammary gland factor) and specific gene expression in T lymphocytes. Proc Natl Acad Sci U S A 92: 10772–10776. 41. Plagnol V, Howson JM, Smyth DJ, Walker N, Hafler JP, et al. (2011) Genome- wide association analysis of autoantibody positivity in type 1 diabetes cases. PLoS Genet 7: e1002216. 10.1371/journal.pgen.1002216 [doi]. 42. Howson JM, Rosinger S, Smyth DJ, Boehm BO, Todd JA (2011) Genetic analysis of adult-onset autoimmune diabetes. Diabetes 60: 2645–2653. db11- 0364 [pii];10.2337/db11-0364 [doi]. 43. Howson JM, Walker NM, Smyth DJ, Todd JA (2009) Analysis of 19 genes for association with type I diabetes in the Type I Diabetes Genetics Consortium AG490 Prevents and Reverses Diabetes families. Genes Immun 10 Suppl 1: S74–S84. gene200996 [pii];10.1038/ gene.2009.96 [doi]. 44. Barrett JC, Clayton DG, Concannon P, Akolkar B, Cooper JD, et al. (2009) Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 41: 703–707. 45. Seydel F, Garrigan E, Stutevoss B, Belkin N, Makadia B, et al. (2008) GM-CSF induces STAT5 binding at epigenetic regulatory sites within the Csf2 promoter of non-obese diabetic (NOD) mouse myeloid cells. J Autoimmun 31: 377–384. 46. Rumore-Maton B, Elf J, Belkin N, Stutevoss B, Seydel F, et al. (2008) M-CSF and GM-CSF regulation of STAT5 activation and DNA binding in myeloid cell differentiation is disrupted in nonobese diabetic mice. Clin Dev Immunol 2008: 769795. 47. Berthier CC, Zhang H, Schin M, Henger A, Nelson RG, et al. (2009) Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes 58: 469–477. 48. Thirone AC, Jebailey L, Bilan PJ, Klip A (2006) Opposite Effect of JAK2 on Insulin-Dependent Activation of Mitogen-Activated Protein Kinases and Akt in Muscle Cells: Possible Target to Ameliorate Insulin Resistance. Diabetes 55: 942–951. 49. Rezende LF, Vieira AS, Negro A, Langone F, Boschero AC (2009) Ciliary neurotrophic factor (CNTF) signals through STAT3-SOCS3 pathway and protects rat pancreatic islets from cytokine-induced apoptosis. Cytokine 46: 65–71. 50. Zhang F, Zhang Q, Tengholm A, Sjoholm A (2006) Involvement of JAK2 and Src kinase tyrosine phosphorylation in human growth hormone-stimulated increases in cytosolic free Ca2+ and insulin secretion. Am J Physiol Cell Physiol 291: C466–C475. 51. O’Shea JJ (2004) Targeting the Jak/STAT pathway for immunosuppression. Ann Rheum Dis 63 Suppl 2: ii67–ii71. 52. Ghoreschi K, Laurence A, O’Shea JJ (2009) Janus kinases in immune cell signaling. Immunol Rev 228: 273–287. 53. Imada K, Leonard WJ (2000) The Jak-STAT pathway. Mol Immunol 37: 1–11. 54. O’Shea JJ, Park H, Pesu M, Borie D, Changelian P (2005) New strategies for immunosuppression: interfering with cytokines by targeting the Jak/Stat pathway. Curr Opin Rheumatol 17: 305–311. 55. Ohtani T, Ishihara K, Atsumi T, Nishida K, Kaneko Y, et al. (2000) Dissection of signaling cascades through gp130 in vivo: reciprocal roles for S. Immunity 12: 95–105. 56. Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, et al. (1997) Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci U S A 94: 7239–7244. 57. Bates SH, Gardiner JV, Jones RB, Bloom SR, Bailey CJ (2002) Acute stimulation of glucose uptake by leptin in l6 muscle cells. Horm Metab Res 34: 111–115. 58. Wang X, Shaw S, Amiri F, Eaton DC, Marrero MB (2002) Inhibition of the Jak/STAT signaling pathway prevents the high glucose-induced increase in tgf- beta and fibronectin synthesis in mesangial cells. Diabetes 51: 3505–3509. 59. Steinman RM (2003) Some interfaces of dendritic cell biology. APMIS 111: 675–697. 60. Steinman RM, Hawiger D, Nussenzweig MC (2003) Tolerogenic dendritic cells. Annu Rev Immunol 21: 685–711. 61. Kishimoto H, Sprent J (2001) A defect in central tolerance in NOD mice. Nat Immunol 2: 1025–1031. 62. Davoodi-Semiromi A, Copper-DeHoff R (2011) Note to Readers on: Long term treatment with ACE inhibitor enalapril decreases body weight gain and increases life span in rats. Biochemical Pharmacology In press 2012, doi:10.1016/j.bcp.2011.12.033. PLoS ONE | www.plosone.org 12 May 2012 | Volume 7 | Issue 5 | e36079